NASDAQ:RCKT

Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

$19.65

+1.26 (+6.85%)

(As of 12/2/2022 02:40 PM ET)

Add

Compare

Today's Range: $17.88
▼
$19.68
50-Day Range: $12.37
▼
$20.70
52-Week Range: $7.57
▼
$25.62

Volume: 19,915 shs
Average Volume: 731,330 shs
Market Capitalization: $1.49 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $56.40

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 187.0% Upside
$56.40 Price Target
Short Interest: Healthy
10.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.98) to ($2.95) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.96 out of 5 stars

Medical Sector

22nd out of 1,052 stocks

Pharmaceutical Preparations Industry

8th out of 514 stocks

4.5

Analyst's Opinion

Consensus Rating
Rocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $56.40, Rocket Pharmaceuticals has a forecasted upside of 187.0% from its current price of $19.65.
Amount of Analyst Coverage
Rocket Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
10.32% of the outstanding shares of Rocket Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in Rocket Pharmaceuticals has recently decreased by 16.91%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Rocket Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rocket Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Rocket Pharmaceuticals is -0.81.

2.2

News and Social Media Coverage

News Sentiment
Rocket Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Rocket Pharmaceuticals this week, compared to 6 articles on an average week.
Search Interest
Only 10 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rocket Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,999,997.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
33.67% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
98.02% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.98) to ($2.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rocket Pharmaceuticals is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rocket Pharmaceuticals is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rocket Pharmaceuticals has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

November 29, 2022 | seekingalpha.com

Rocket Pharmaceuticals: 2 Regulatory Filings In 2023 Could Propel It Higher

November 21, 2022 | finance.yahoo.com

Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 18, 2022 | seekingalpha.com

Rocket Pharmaceuticals: Intriguing Potential

November 4, 2022 | finance.yahoo.com

Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

November 3, 2022 | finance.yahoo.com

Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses

October 30, 2022 | msn.com

Hogs’ ‘Rocket’ Sanders Still Has Goals in Front of Him

October 27, 2022 | finance.yahoo.com

Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

October 14, 2022 | finance.yahoo.com

Alkermes, Allakos, and Other Stocks See Action From Activist Investors

October 12, 2022 | finance.yahoo.com

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

October 11, 2022 | finance.yahoo.com

Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect?

October 10, 2022 | finance.yahoo.com

Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa

October 4, 2022 | nasdaq.com

Rocket Pharmaceuticals Adds 10%; Prices 6.8 Mln Share Offering

October 4, 2022 | nasdaq.com

Rocket Pharma Prices Public Offering Of 6.80 Mln Shares At $14.75/shr

September 30, 2022 | seekingalpha.com

Rocket's gene therapy for heart disease shows promise in children/adults in phase 1 trial

September 30, 2022 | finance.yahoo.com

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

September 27, 2022 | markets.businessinsider.com

Needham Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)

September 27, 2022 | finance.yahoo.com

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference

September 20, 2022 | nasdaq.com

Rocket Pharma To Buy Renovacor For $2.60/ Share In Stock

September 20, 2022 | marketwatch.com

Rocket Pharmaceuticals to Acquire Renovacor in All-Stk Transaction for Implied Value of About $2.60 Per Shr >RCKT

September 20, 2022 | technews.tmcnet.com

RCKT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Rocket Pharmaceuticals, Inc. Is Fair to Shareholders

September 20, 2022 | seekingalpha.com

Rocket to acquire heart gene-therapy developer Renovacor in all-stock deal

September 20, 2022 | finance.yahoo.com

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

September 20, 2022 | finance.yahoo.com

Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases

September 16, 2022 | finance.yahoo.com

Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

September 16, 2022 | msn.com

Rocket Lab celebrates 30th launch and 150th satellite sent to orbit

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings: 11/03/2021
Today: 12/02/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/23/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RCKT
CUSIP: N/A
CIK: 1281895
Web: www.rocketpharma.com
Phone: (646) 440-9100
Fax: 646-224-9585
Employees: 151
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $56.40
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +187.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-169,070,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.01%
Return on Assets: -44.15%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 10.31
Quick Ratio: 10.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.85 per share
Price / Book: 4.05

Miscellaneous

Outstanding Shares: 75,680,000
Free Float: 50,201,000
Market Cap: $1.49 billion
Optionable: Optionable
Beta: 1.48

Key Executives

Dr. Gaurav D. Shah M.D. (Age 47)
CEO & Director
Comp: $920.2k

Ms. Kinnari Patel M.B.A. (Age 43)
MBA, Pharm.D., PharmD, Pres & COO
Comp: $717.82k

Mr. Martin Louis Wilson J.D. (Age 46)
Gen. Counsel, Chief Compliance Officer & Sr. VP
Comp: $149.95k

Mr. Jonathan Schwartz (Age 58)
Chief Medical Officer & Sr. VP of Clinical Devel.
Comp: $557.79k

Mr. John C. Militello CPA (Age 49)
CPA, Interim Principal Financial Officer, VP, Sr. Controller, Treasurer & Principal Accounting Officer

Mr. Mayo Pujols
Chief Technical Officer, Exec. VP & Director

Mayur Kasetty M.B.A.
M.D., Bus. Devel. & Operations and Investor Relations Lead

Ms. Jessie Yeung M.B.A.
VP of Investor Relations & Corp. Fin.

Kevin Giordano
Director of Corp. Communications

Ms. Isabel Carmona J.D.
Sr. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.
What is Rocket Pharmaceuticals' stock price forecast for 2023?: 10 equities research analysts have issued twelve-month price targets for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they expect the company's stock price to reach $56.40 in the next year. This suggests a possible upside of 206.7% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.
How have RCKT shares performed in 2022?: Rocket Pharmaceuticals' stock was trading at $21.83 at the beginning of the year. Since then, RCKT shares have decreased by 15.8% and is now trading at $18.39.
View the best growth stocks for 2022 here.
When is Rocket Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our RCKT earnings forecast.
How were Rocket Pharmaceuticals' earnings last quarter?: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) posted its quarterly earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.19. During the same period last year, the company earned ($0.53) EPS.
What other stocks do shareholders of Rocket Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?: Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."
Who are Rocket Pharmaceuticals' major shareholders?: Rocket Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.94%), Vanguard Group Inc. (4.52%), State Street Corp (4.48%), Price T Rowe Associates Inc. MD (2.17%), Assenagon Asset Management S.A. (2.10%) and Dimensional Fund Advisors LP (1.17%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Rocket Pharmaceuticals?: Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Rocket Pharmaceuticals' stock price today?: One share of RCKT stock can currently be purchased for approximately $18.39.
How much money does Rocket Pharmaceuticals make?: Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.39 billion. The biotechnology company earns $-169,070,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.
How many employees does Rocket Pharmaceuticals have?: The company employs 151 workers across the globe.
How can I contact Rocket Pharmaceuticals?: Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (646) 440-9100, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

Rocket Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™